JNJ — All updates

6 entries loaded; 1 direction changes

Filter loaded records
Schwab NetworkPublished 2026-11-12
“The Big 3: JNJ, LLY, AAPL”
$JNJBullish
AI summary · JNJ's trend favors the upside; the speaker plans to enter near the current ~283 level via a December call spread (36 days out, 283/270) costing about $3. If momentum continues, he expects a rise toward 300 over the next month; on weakness he prefers buying near 272-273, and a fall below 270 would be an attractive long-term entry.

You have Johnson & Johnson stock as your first trade here. How do you view Johnson & Johnson now? We see them rising in this morning's session.

In fact, it's more like an almost unexpected success . We have risen 46% from those lows, which were largely the lowest levels in 52 weeks. What we can see here is that the recent highs of 285.48 were reached today.

We have fallen back a little from that, but it is clear that this is the level that needs to be surpassed in the upward direction. These older highs here, which also represented some price volatility , have shown a kind of difficulty in breaking through the 281 level.

This also stands out as a potential support zone. 265 is also our recent relative low.

Schwab NetworkPublished 2026-10-29
“The Big 3: AAPL, JNJ, MMM”
$JNJBullish
Verified InvestingPublished 2026-10-13
“What Is Implied Volatility? Vega Explained On A Live J&J Trade”
$JNJBullish
AI summary · Contrarian long JNJ call: after a 5% post-earnings drop below 250, a bounce toward 250, 260 and 270 is expected. Flow is call-heavy, but IV rank, though down from 80 to 90 to about 62, is still not cheap and needs a larger move; the January 15, 2027 260 call gives a cheaper entry.

we decided to pass on Johnson & Johnson because the puts were too expensive. Johnson & Johnson posted their earnings and the market is falling. That is okay.

My primary is a contrarian desk and that's is how I'm going to play it Johnson & Johnson today. I'm going to revisit that same setup and see if we can flip the script and do some TA and um find it for a call today. See if that environment is fit.

Schwab NetworkPublished 2026-10-13
“Tuesday's First Moves: WFC Mixed Earnings, JNJ Beat & Raise, DPZ Slides”
$JNJNo side taken
AI summary · JNJ beat on profit and revenue yet shares fell about 4%: pharma grew on Tremfya while Stelara declined, and medical technology rose only 2.5% to $8.6B, below expectations — blamed on the Middle East conflict, European austerity and China price pressure, the source of the stock's weakness.

Let's talk about Johnson & Johnson. At Johnson & Johnson, the picture is weaker , with shares under pressure and down about 4% despite the company beating expectations in net profit.

Earnings amounted to $2.59 per share . Analysts had expected $2.53 per share. Revenues also recorded a slight increase, reaching $25.4 billion. The market had been expecting $25.25 billion for Johnson & Johnson, but they noted there would be some impact on the medical technology sector .

That was the weakest point, and some of that is due to the geopolitical conflict they mentioned. Sales outside the United States were essentially stable . Once again, total revenues reached $25.4 billion, while the expected amount was $25.25 billion.

Verified InvestingPublished 2026-10-06
“Options 101 what are puts”
$JNJBearish
AI summary · JNJ stock has bearish technical momentum targeting 245; however, the trade thesis was abandoned due to unfavorable options metrics (high IV, low delta, bullish put/call ratio).

Okay, guys. Today, I have a great setup on Johnson & Johnson. The code is JNJ. Okay, guys. With Johnson & Johnson in the picture, I want you to focus on this particular part. It has been experiencing selling pressure over the past four days, with a slight rebound today during daily trading, turning green, but it is heading downwards.

Stock MoePublished 2026-09-13
“CONGRESS OWNS THESE 10 STOCKS 🚨 The President Owns 5 Of Them Too (Best Stocks To Buy Now)”
$JNJBullish
AI summary · JNJ is a strong buy; rising healthcare costs drive its performance, making it the top performer among the discussed stocks.

Johnson and Johnson. I like that one. That's a good good play.

Johnson and Johnson, remember I told you that was a good one? Up 29.1% so far. Healthcare is that one play that everybody wants. Healthcare. The costs keep getting passed on to consumers.

It keeps going higher. Johnson and Johnson's just it's a win.

Uh the best performer this of the 10 this year and the name that gets the least attention. It's because it's not tech.

That's the earliest record
All updates for other tickers
Follow $JNJ30-day free trial
Start trial